Novocure's Optune Lua Receives Japanese Approval for Advanced NSCLC Treatment
核心洞察
Japan's Ministry of Health, Labour and Welfare approved Optune Lua (搜索) for concurrent use with PD-1 (搜索)/PD-L1 (搜索) inhibitors in adult patients with unresectable advanced/recurrent NSCLC who progressed after platinum-based chemotherapy.
The approval was supported by the Phase 3 LUNAR trial, which demonstrated a statistically significant 3.3-month extension in median overall survival (13.2 vs 9.9 months, P=0.04) for patients treated with Optune Lua (搜索).
The device showed particularly strong results when combined with PD-1 (搜索)/PD-L1 (搜索) inhibitors alone, extending median overall survival by more than 8 months (19.0 vs 10.8 months, P=0.02).
Japan's Ministry of Health, Labour and Welfare (MHLW) has approved Novocure (搜索)'s Optune Lua (搜索) for concurrent use with PD-1 (搜索)/PD-L1 (搜索) inhibitors in adult patients with unresectable advanced/recurrent non-small cell lung cancer (NSCLC) who have progressed on or after platinum-based chemotherapy. The approval marks a significant milestone for tumor treating fields (TTFields) technology in the Japanese market, where approximately 120,000 patients are diagnosed with NSCLC annually.
Phase 3 LUNAR Trial Results Drive Approval
The MHLW approval was supported by results from the pivotal Phase 3 LUNAR trial, a prospective, randomized, open-label, multicenter study that compared Optune Lua (搜索) concurrent with PD-1 (搜索)/PD-L1 (搜索) inhibitors or docetaxel to standard therapy alone in patients with metastatic NSCLC who progressed during or after platinum-based therapy.
The trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful 3.3-month extension in median overall survival (P=0.04) for patients treated with Optune Lua (搜索) concurrently with a PD-1 (搜索)/PD-L1 (搜索) inhibitor or docetaxel (n=145). The experimental group achieved a median OS of 13.2 months (95% CI, 10.3 to 15.5 months) compared to 9.9 months (95% CI, 8.2 to 12.2 months) in the control arm (n=146).
Strongest Efficacy Observed with Immunotherapy Combination
The LUNAR study included two pre-specified powered secondary endpoints, with the first meeting statistical significance. Patients treated with Optune Lua (搜索) concurrently with a PD-1 (搜索)/PD-L1 (搜索) inhibitor (n=70) demonstrated a median OS of 19.0 months (95% CI, 10.6 to 28.2 months) compared to 10.8 months (95% CI, 8.3 to 17.6 months) in patients treated with a PD-1/PD-L1 inhibitor alone (n=71), representing a statistically significant extension of more than 8.0 months (P=0.02).
The second secondary endpoint, assessing Optune Lua (搜索) with docetaxel versus docetaxel alone, showed a positive trend but did not meet statistical significance. Patients receiving Optune Lua and docetaxel (n=75) had a median OS of 11.1 months (95% CI, 8.2 to 13.9 months) compared to 8.9 months (95% CI, 6.5 to 11.3 months) for docetaxel alone (n=75), a 2.2-month extension that did not provide statistically significant benefit.
Favorable Safety Profile
Device-related adverse events occurred in 63.1% of patients (n=89), consisting primarily of skin-related disorders under the transducer arrays. The majority of these events were low grade (Grade 1-2), with only 4% (n=6) experiencing Grade 3 skin toxicity that required a treatment break. Notably, there were no Grade 4 or Grade 5 toxicities related to Optune Lua (搜索), and no device-related adverse events caused death.
"The Phase 3 LUNAR trial showed that use of Optune Lua (搜索) resulted in improved overall survival rates without severe side effects, resulting in a significant benefit for patients with this aggressive disease," said Dr. Tetsuya Mitsudomi, President of Izumi City General Hospital.
Patient Population and Study Design
The trial enrolled patients with well-balanced baseline characteristics: median age was 65 years (range, 22-86), 66% male and 34% female, with 96% of patients having an ECOG performance status of 0-1. PD-L1 (搜索) expression data were collected from 83% of patients enrolled at U.S. sites and were well balanced across the four cohorts.
Continuous 150 kHz TTFields therapy was delivered to the thoracic region using the NovoTTF device system, with treatment consisting of four electrically insulated electrode arrays worn on the chest. Array layouts were customized based on sex, disease burden, and patient body size, with the goal of achieving an average usage of at least 75% of each day.
Addressing Critical Medical Need
"Lung cancer is the leading cause of cancer-related death worldwide, and unfortunately, in Japan the number of cases continue to increase, which is why we see an urgent need for innovative treatment options for this disease," said Frank Leonard, President of Novocure (搜索). "Novocure is focused on launching Optune Lua (搜索) as quickly as possible in Japan so that patients with non-small cell lung cancer experiencing a progression after initial platinum-based treatment have access to our therapy."
Optune Lua (搜索) is a wearable, portable medical device that produces alternating electric fields known as Tumor Treating Fields, which are delivered through non-invasive, wearable arrays. TTFields exert physical forces on the electrically charged components of dividing cancer cells, resulting in cancer cell death while not significantly affecting healthy cells due to their different properties including division rate, morphology, and electrical characteristics.